Business ❯Pharmaceutical Industry ❯Stock Market ❯Investor Sentiment
The Danish pharmaceutical giant pivots strategically, securing global rights to UBT251 to compete with Eli Lilly's advanced treatments in the expanding weight-loss drug market.
